Skip to main content
Erschienen in: Neurological Sciences 3/2021

10.09.2020 | Letter to the Editor

Optic neuritis associated with sunitinib

verfasst von: Seunghee Na, Taewon Kim

Erschienen in: Neurological Sciences | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Excerpt

Sunitinib malate is a receptor tyrosine kinase inhibitor commonly used to control angiogenesis and proliferation in cancer. Fatigue, gastrointestinal symptoms, hypertension, and myelosuppression are common adverse effects of sunitinib and are usually manageable. Although adverse neurological effects associated with sunitinib are rare [1], serious and unexpectable adverse reactions can be seen with widespread use of targeted anticancer therapies. Herein, we describe a rare case of optic neuritis (ON) in a patient with metastatic renal cell carcinoma treated with sunitinib. …
Literatur
2.
Zurück zum Zitat Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions: I. Background, description, and instructions for use. Jama 242(7):623–632CrossRef Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions: I. Background, description, and instructions for use. Jama 242(7):623–632CrossRef
3.
Zurück zum Zitat Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA, D'Amore PA (2008) VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma. J Exp Med 205(2):491–501CrossRef Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA, D'Amore PA (2008) VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma. J Exp Med 205(2):491–501CrossRef
4.
Zurück zum Zitat Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E, Antón-Aparicio L (2011) New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther 10(12):2215–2223CrossRef Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E, Antón-Aparicio L (2011) New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther 10(12):2215–2223CrossRef
5.
Zurück zum Zitat Kanaan Z, Kulairi Z, Titianu M, Saha S, Kumar S (2014) Guillain-Barré syndrome following treatment with sunitinib malate. Case Rep Oncol Med 2014:1–2 Kanaan Z, Kulairi Z, Titianu M, Saha S, Kumar S (2014) Guillain-Barré syndrome following treatment with sunitinib malate. Case Rep Oncol Med 2014:1–2
6.
Zurück zum Zitat Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, Matsuo K, Arisato T, Osame M (1998) Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow–Fukase (POEMS) syndrome. Muscle Nerve 21(11):1390–1397CrossRef Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, Matsuo K, Arisato T, Osame M (1998) Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow–Fukase (POEMS) syndrome. Muscle Nerve 21(11):1390–1397CrossRef
7.
Zurück zum Zitat Babu KG, Attili VSS, Bapsy P, Anupama G (2007) Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 27(1):43–44CrossRef Babu KG, Attili VSS, Bapsy P, Anupama G (2007) Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 27(1):43–44CrossRef
9.
Zurück zum Zitat Monge KS, Gálvez-Ruiz A, Alvárez-Carrón A, Quijada C, Matheu A (2015) Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol 29(3):227–231CrossRef Monge KS, Gálvez-Ruiz A, Alvárez-Carrón A, Quijada C, Matheu A (2015) Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol 29(3):227–231CrossRef
Metadaten
Titel
Optic neuritis associated with sunitinib
verfasst von
Seunghee Na
Taewon Kim
Publikationsdatum
10.09.2020
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 3/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04713-x

Weitere Artikel der Ausgabe 3/2021

Neurological Sciences 3/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.